Lee, chang-han
Ph.D. / Assistant professor
Research
Research Field
Monoclonal antibodies (mAb) have been used as therapeutic agents for various diseases, and immunoglobulin G (IgG) is mainly used among antibody isotypes due to its structural and functional properties. So far, regardless of the purpose of the therapeutic antibody, wild-type IgG has been mainly used, but recently, the engineered antibodies with various strategies according to the role of the therapeutic antibody have been used to maximize the therapeutic efficacy.In our laboratory, we are developing a variety of novel therapeutic antibodies for cancer, Alzheimer's disease, COVID-19, and etc.
1) Antibody discovery: discovery of new therapeutic antibodies against new antigens
2) Antibody engineering: Improving the function of therapeutic antibody according to the mechanism of action of the antigen
3) Identification of the immunological role of Fc receptors
4) Development of cell therapy using antibodies
Keyword
Antibody discovery and engineering, Fc receptors, Complement, Effector cells, Onco-immunologyEducation
- 2000-2007 Bachelor: Dept. of Chemical and Biological Engineering, Ajou University
- 2007-2013 Ph.D: Dept. of Molecular Science and Technology, Ajou University, Advisor: Dr. Yong-Sung Kim (http://antibody.ajou.ac.kr/)
Career
- 2013-2018 Postoctoral research fellow, The University of Texas at Austin (PI Dr. George Georigou)
- 2018-2020 Research associate, The University of Texas at Austin (PI Dr. George Georigou)
- 2020-Now, Assistant Professor, Department of Biomedical Sciences at Seoul National University College of Medicine
Publication
- Aram Lyu#, Todd A Triplett#, Seo Hee Nam, Zicheng Hu, Dhivya Arasappan, Wesley H Godfrey, Rachel Y Ames, Adviti Sarang, Hilary J Selden, Chang-Han Lee, George Georgiou, Terzah M Horton, Lauren I R Ehrlich*, Tumor-associated myeloid cells provide critical support for T-ALL. Blood 2020 July 7
- Jiwon Lee, Bryan S. Der, Christos S. Karamitros, Wenzong Li, Nicholas M. Marshall, Oana I. Lungu, Aleksandr E. Miklos, Jianqing Xu, Tae Hyun Kang, Chang‐Han Lee, Bing Tan, Randall A. Hughes, Sang Taek Jung, Gregory C. Ippolito, Jeffrey J. Gray, Yan Zhang, Brian Kuhlman, George Georgiou*, Andrew D. Ellington* Computer‐based engineering of thermostabilized antibody fragments. AIChE Journal 2019 Nov 19
- Chang-Han Lee†, Tae Hyun Kang†, Ophélie Godon, Makiko Watanabe, George Delidakis, Caitlin M. Gillis, Delphine Sterlin, David Hardy, Michel Cogné, Lynn E. Macdonald, Andrew. J. Murphy, Naxin Tu, Jiwon Lee, Jonathan R. McDaniel, Emily Makowski, Peter Tessier, Aaron S. Meyer, Pierre Bruhns*, and George Georgiou* An Engineered Human Fc Domain that Behaves like a pH-Toggle Switch for Ultra-Long Circulation Persistence. Nature Communications 2019 Nov 6 10:5031 († equally contributed).
- Tae Hyun Kang†, Chang-Han Lee†, George Delidakis, Jiwon Jung, Odile Richard-Le Goff, Jiwon Lee, Jin Eyun Kim, Wissam Charab, Pierre Bruhns, and George Georgiou* (2019) An Engineered Human Fc variant with Exquisite Selectivity for FcγRIIIaV158 Reveals that Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis with GM-CSF-differentiated Macrophages. Frontiers in Immunology 2019 Mar. 27. 10: 562 († equally contributed).
- Jonathan R McDaniel, Stephanie C Pero, William N Voss, Girja S Shukla, Yujing Sun, Sebastian Schaetzle, Chang-Han Lee, Andrew P Horton, Seth Harlow, Jimmy Gollihar, Jared W Ellefson, Christopher C Krag, Yuri Tanno, Nikoletta Sidiropoulos, George Georgiou, Gregory C Ippolito, David N Krag* (2018) Identification of Tumor-Reactive B Cells and Systemic IgG in Breast Cancer Based on Clonal Frequency in the Sentinel Lymph Node. Cancer Immunology, Immunotherapy 2018 May; 67(5): 729-738.
